Natriuretic Peptide System and Cardiovascular Disease

Overview

Journal Heart Views

Specialty Cardiology & Vascular Diseases

Date 2010 Nov 3

PMID 21042458

Citations 20

Authors

Cacciapuoti Federico

Affiliations

Soon will be listed here.

Abstract

The mammalian Natriuretic Peptide (NP) system consists of neuro-hormones, such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), c-type natriuretic peptide (CNP), and the N-Terminal fragment of BNP (NT-pro-BNP). In response to some cardiovascular derangement the heart (acting as an endocrine organ), brain and other structures secretes natriuretic peptides in an attempt to restore normal circulatory conditions. Their actions are modulated through membrane-bound guanylyl cyclased (GC) receptors. They induce diuresis, natriuresis and vasodilation in the presence of congestive heart failure. These neuro-hormones also play a role in the suppression of neointimal formation after vascular injury. In addition, they act as antifibrotic and antihypertrophic agents preventing cardiac remodeling after myocardial infarction. Further, NP have diagnostic and prognostic role in heart failure, vasoconstriction, left ventricular late remodeling after MI and others. At present, some drugs such as Nesiritide, NEP inhibitors and vasopeptidase inhibitors were synthetized from NP, to antagonize these cardiovascular derengements. In future, it will be possibile to elaborate some drugs similar to petidase inhibitors and some CNP-like drugs able to reduce many symptoms of cardiovascular derangements without significant side effects.

Citing Articles

Association between antioxidant metabolites and N-terminal fragment brain natriuretic peptides in insulin-resistant individuals.

Anwardeen N, Naja K, Elrayess M Cardiovasc Endocrinol Metab. 2024; 13(2):e0303.

PMID: 38706534 PMC: 11068140. DOI: 10.1097/XCE.0000000000000303.

The Role of Serum NT-proBNP for Predicting Left Ventricular Systolic Dysfunction in Hospitalized Patients in Sri Lanka.

Chaminda Rathnayake B, Illeperuma R, Jayasinghe S, Fawcett T, Maduwage K, Thilak Jayalath W EJIFCC. 2024; 34(4):287-296.

PMID: 38303755 PMC: 10828538.

Influence of fasting plasma glucose-lowering rate on BNP levels in type 2 diabetes mellitus patients with coronary microcirculation dysfunction.

Zhang Z, Chen Y, Wang Q, Xie L, Shan Y, Yang N Hormones (Athens). 2022; 22(1):33-43.

PMID: 36369625 DOI: 10.1007/s42000-022-00404-8.

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.

Raj P, Sayfee K, Parikh M, Yu L, Wigle J, Netticadan T Molecules. 2021; 26(16).

PMID: 34443591 PMC: 8401506. DOI: 10.3390/molecules26165006.

Fibrosis-4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction.

Nakashima M, Sakuragi S, Miyoshi T, Takayama S, Kawaguchi T, Kodera N ESC Heart Fail. 2021; 8(3):2240-2247.

PMID: 33760403 PMC: 8120399. DOI: 10.1002/ehf2.13317.

References

Elnoamany M, Abdelhameed A . Mitral annular motion as a surrogate for left ventricular function: correlation with brain natriuretic peptide levels. Eur J Echocardiogr. 2005; 7(3):187-98. DOI: 10.1016/j.euje.2005.05.005. View

Svanegaard J, Pindborg T . Atrial natriuretic peptide in congestive heart failure after acute myocardial infarction. Cardiology. 1993; 82(1):1-6. DOI: 10.1159/000175846. View

Hauptman P, Schnitzler M, Swindle J, Burroughs T . Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA. 2006; 296(15):1877-84. PMC: 2840641. DOI: 10.1001/jama.296.15.1877. View

McDonagh T, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie H . NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail. 2004; 6(3):269-73. DOI: 10.1016/j.ejheart.2004.01.010. View

Sackner-Bernstein J, Skopicki H, Aaronson K . Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005; 111(12):1487-91. DOI: 10.1161/01.CIR.0000159340.93220.E4. View

Masson S, Latini R, Anand I, Barlera S, Angelici L, Vago T . Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008; 52(12):997-1003. DOI: 10.1016/j.jacc.2008.04.069. View

Kasama S, Toyama T, Kumakura H, Takayama Y, Ishikawa T, Ichikawa S . Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure. J Nucl Med. 2004; 45(7):1108-13. View

Heringer-Walther S, Moreira M, Wessel N, Wang Y, Moreira Ventura T, Schultheiss H . Does the C-type natriuretic peptide have prognostic value in chagas disease and other dilated cardiomyopathies?. J Cardiovasc Pharmacol. 2007; 48(6):293-8. DOI: 10.1097/01.fjc.0000249892.22635.46. View

de Lemos J, McGuire D, Drazner M . B-type natriuretic peptide in cardiovascular disease. Lancet. 2003; 362(9380):316-22. DOI: 10.1016/S0140-6736(03)13976-1. View

10.

Lee C, Burnett Jr J . Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007; 12(2):131-42. DOI: 10.1007/s10741-007-9016-3. View

11.

Heeschen C, Hamm C, Mitrovic V, Lantelme N, White H . N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004; 110(20):3206-12. DOI: 10.1161/01.CIR.0000147611.92021.2B. View

12.

Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K . C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol. 2005; 45(4):608-16. DOI: 10.1016/j.jacc.2004.10.067. View

13.

Sudoh T, Minamino N, Kangawa K, Matsuo H . C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990; 168(2):863-70. DOI: 10.1016/0006-291x(90)92401-k. View

14.

Tokudome T, Horio T, Soeki T, Mori K, Kishimoto I, Suga S . Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-1 signaling pathways. Endocrinology. 2004; 145(5):2131-40. DOI: 10.1210/en.2003-1260. View

15.

Rosenzweig A, Seidman C . Atrial natriuretic factor and related peptide hormones. Annu Rev Biochem. 1991; 60:229-55. DOI: 10.1146/annurev.bi.60.070191.001305. View

16.

Crozier I, Nicholls M, Ikram H, Espiner E, Yandle T . Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition. Clin Exp Pharmacol Physiol. 1989; 16(5):417-24. DOI: 10.1111/j.1440-1681.1989.tb01579.x. View

17.

Sackner-Bernstein J, Kowalski M, Fox M, Aaronson K . Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005; 293(15):1900-5. DOI: 10.1001/jama.293.15.1900. View

18.

Furuya M, Miyazaki T, Honbou N, Kawashima K, Ohno T, Tanaka S . C-type natriuretic peptide inhibits intimal thickening after vascular injury. Ann N Y Acad Sci. 1995; 748:517-23. DOI: 10.1111/j.1749-6632.1994.tb17352.x. View

19.

Drummond A, Beckett P, Brown P, Bone E, Davidson A, Galloway W . Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci. 1999; 878:228-35. DOI: 10.1111/j.1749-6632.1999.tb07688.x. View

20.

Kimmelstiel C, Perrone R, Kilcoyne L, Souhrada J, Udelson J, Smith J . Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure. Cardiology. 1996; 87(1):46-53. DOI: 10.1159/000177059. View